These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38819948)

  • 21. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity.
    Jesus D; Larosa M; Henriques C; Matos A; Zen M; Tomé P; Alves V; Costa N; Le Guern V; Iaccarino L; Costedoat-Chalumeau N; Doria A; Inês LS
    Ann Rheum Dis; 2021 Dec; 80(12):1568-1574. PubMed ID: 34407927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [No Abstract]   [Full Text] [Related]  

  • 23. Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting.
    Anjo C; Mascaró JM; Espinosa G; Cervera R
    Scand J Rheumatol; 2019 Nov; 48(6):469-473. PubMed ID: 31264525
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparisons of SLE-DAS and SLEDAI-2K and classification of disease activity based on the SLE-DAS with reference to patient-reported outcomes.
    Onishi A; Tsuji H; Takase Y; Nakakubo Y; Iwasaki T; Kozuki T; Yoshida T; Shirakashi M; Onizawa H; Hiwa R; Kitagori K; Akizuki S; Nakashima R; Yoshifuji H; Tanaka M; Morinobu A
    Rheumatology (Oxford); 2023 Dec; 62(12):3909-3915. PubMed ID: 36943365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Belimumab is Able to Induce a Significant Improvement of Joint Activity Status in Patients Diagnosed with Systemic Lupus Erythematosus: Results From a 12-Month Longitudinal Study.
    Ceccarelli F; Cipriano E; Natalucci F; Perricone C; Olivieri G; Orefice V; Morello F; Alessandri C; Spinelli FR; Conti F
    Isr Med Assoc J; 2020 Jul; 22(7):415-419. PubMed ID: 33236565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus.
    Cavazzana I; Kumar R; Pozzari C; Ottaviani R; Fredi M; Piantoni S; Andreoli L; Tincani A; Franceschini F
    Lupus; 2019 Aug; 28(9):1074-1081. PubMed ID: 31296140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Iaccarino L; Bettio S; Reggia R; Zen M; Frassi M; Andreoli L; Gatto M; Piantoni S; Nalotto L; Franceschini F; Larosa M; Fredi M; Punzi L; Tincani A; Doria A
    Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Smoking reduces the efficacy of belimumab in mucocutaneous lupus.
    Parodis I; Gomez A; Frodlund M; Jönsen A; Zickert A; Sjöwall C; Bengtsson AA; Gunnarsson I
    Expert Opin Biol Ther; 2018 Aug; 18(8):911-920. PubMed ID: 29958508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
    Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
    Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies.
    Parodis I; Emamikia S; Gomez A; Gunnarsson I; van Vollenhoven RF; Chatzidionysiou K
    Expert Opin Biol Ther; 2019 Feb; 19(2):157-168. PubMed ID: 30571926
    [No Abstract]   [Full Text] [Related]  

  • 32. Association of disease activity with depression and anxiety in systemic lupus erythematosus: A comparison of SLEDAI-2K and SLE-DAS.
    Yang L; Gu B; Wang X; Ren Q; Shen M; Su D
    Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38305645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D
    Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
    Parodis I; Sjöwall C; Jönsen A; Ramsköld D; Zickert A; Frodlund M; Sohrabian A; Arnaud L; Rönnelid J; Malmström V; Bengtsson AA; Gunnarsson I
    Autoimmun Rev; 2017 Apr; 16(4):343-351. PubMed ID: 28216072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A; Stohl W; Schwarting A; Okada M; Scheinberg M; van Vollenhoven R; Hammer AE; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2018 Aug; 70(8):1256-1264. PubMed ID: 29671280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
    Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
    Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initiation of belimumab with higher daily prednisolone is effective for rapid glucocorticoid reduction: A 96-week retrospective study.
    Yamane T; Hashiramoto A
    Lupus; 2024 May; 33(6):598-607. PubMed ID: 38509864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study.
    Wang D; Shan C; Liu J; Zhang R; Zhu G; Gao T; Chang H; Gao S; Bai C; Nie N; Zhang Q; Lin Y
    Front Immunol; 2022; 13():1067721. PubMed ID: 36591249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
    Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
    Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland.
    von Kempis J; Duetsch S; Reuschling N; Villiger R; Villiger PM; Vallelian F; Schaer DJ; Mueller RB
    Swiss Med Wkly; 2019 Feb; 149():w20022. PubMed ID: 30852830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.